JP6026013B2 - 新規キノロン誘導体 - Google Patents
新規キノロン誘導体 Download PDFInfo
- Publication number
- JP6026013B2 JP6026013B2 JP2015548889A JP2015548889A JP6026013B2 JP 6026013 B2 JP6026013 B2 JP 6026013B2 JP 2015548889 A JP2015548889 A JP 2015548889A JP 2015548889 A JP2015548889 A JP 2015548889A JP 6026013 B2 JP6026013 B2 JP 6026013B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- hydroxy
- oxo
- carboxamido
- acetic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- CWMXRILSIHZXEG-UHFFFAOYSA-N C=CCON(c(nccc1)c1C(O)=C1C(NCC(O)=O)=O)C1=O Chemical compound C=CCON(c(nccc1)c1C(O)=C1C(NCC(O)=O)=O)C1=O CWMXRILSIHZXEG-UHFFFAOYSA-N 0.000 description 1
- OEQTZANVBJRUEO-UHFFFAOYSA-N C=CCON(c1cc(Oc2ccccc2)ccc1C(O)=C1C(NCC(O)=O)=O)C1=O Chemical compound C=CCON(c1cc(Oc2ccccc2)ccc1C(O)=C1C(NCC(O)=O)=O)C1=O OEQTZANVBJRUEO-UHFFFAOYSA-N 0.000 description 1
- IIOLEQVHEMPYPZ-UHFFFAOYSA-N C=CCON(c1cccc(F)c1C(O)=C1C(NCC(O)=O)=O)C1=O Chemical compound C=CCON(c1cccc(F)c1C(O)=C1C(NCC(O)=O)=O)C1=O IIOLEQVHEMPYPZ-UHFFFAOYSA-N 0.000 description 1
- CVSNVXIILYKIMZ-UHFFFAOYSA-N C=CCON(c1ccccc1C(O)=C1C(NCC(O)=O)=O)C1=O Chemical compound C=CCON(c1ccccc1C(O)=C1C(NCC(O)=O)=O)C1=O CVSNVXIILYKIMZ-UHFFFAOYSA-N 0.000 description 1
- GTCQZZZLDABVRZ-UHFFFAOYSA-N CCCON(c1c(C(O)=C2C(NCC(O)=O)=O)[o]cc1)C2=O Chemical compound CCCON(c1c(C(O)=C2C(NCC(O)=O)=O)[o]cc1)C2=O GTCQZZZLDABVRZ-UHFFFAOYSA-N 0.000 description 1
- UZDVTRISPQJECU-UHFFFAOYSA-N CCON(c([s]cc1)c1C(O)=C1C(NCC(O)=O)=O)C1=O Chemical compound CCON(c([s]cc1)c1C(O)=C1C(NCC(O)=O)=O)C1=O UZDVTRISPQJECU-UHFFFAOYSA-N 0.000 description 1
- RBJCMLGWQHEMOF-UHFFFAOYSA-N CCON(c(c(C(O)=C1C(NCC(O)=O)=O)ccc2)c2OC)C1=O Chemical compound CCON(c(c(C(O)=C1C(NCC(O)=O)=O)ccc2)c2OC)C1=O RBJCMLGWQHEMOF-UHFFFAOYSA-N 0.000 description 1
- LFTXYPKIUYJQNH-UHFFFAOYSA-N CN(CC(O)=O)C(C(C(N(c1ccccc11)OCc2ccccc2)=O)=C1O)=O Chemical compound CN(CC(O)=O)C(C(C(N(c1ccccc11)OCc2ccccc2)=O)=C1O)=O LFTXYPKIUYJQNH-UHFFFAOYSA-N 0.000 description 1
- USFGXCUQCQVPLQ-UHFFFAOYSA-N CON(c1c(C(O)=C2C(NCC(O)=O)=O)[s]cc1)C2=O Chemical compound CON(c1c(C(O)=C2C(NCC(O)=O)=O)[s]cc1)C2=O USFGXCUQCQVPLQ-UHFFFAOYSA-N 0.000 description 1
- JIXNFYSYVXWYNX-UHFFFAOYSA-N OC(CNC(C(C(N(c(c1c2)ccc2Oc2ncccc2)OCc2ccccc2)=O)=C1O)=O)=O Chemical compound OC(CNC(C(C(N(c(c1c2)ccc2Oc2ncccc2)OCc2ccccc2)=O)=C1O)=O)=O JIXNFYSYVXWYNX-UHFFFAOYSA-N 0.000 description 1
- NTVWLHJZZNPMRP-UHFFFAOYSA-N OC(CNC(C(C(N(c1c2cccn1)OCCc1ccc(C(F)(F)F)cc1)=O)=C2O)=O)=O Chemical compound OC(CNC(C(C(N(c1c2cccn1)OCCc1ccc(C(F)(F)F)cc1)=O)=C2O)=O)=O NTVWLHJZZNPMRP-UHFFFAOYSA-N 0.000 description 1
- JCIWRCFMPOQZPN-UHFFFAOYSA-N OC(CNC(C(C(N(c1c2cncn1)OCc1ccccc1)=O)=C2O)=O)=O Chemical compound OC(CNC(C(C(N(c1c2cncn1)OCc1ccccc1)=O)=C2O)=O)=O JCIWRCFMPOQZPN-UHFFFAOYSA-N 0.000 description 1
- GYICHNKMWXRAQM-UHFFFAOYSA-N OC(CNC(C(C(N(c1ccccc11)OCc2c[s]c(C(F)(F)F)n2)=O)=C1O)=O)=O Chemical compound OC(CNC(C(C(N(c1ccccc11)OCc2c[s]c(C(F)(F)F)n2)=O)=C1O)=O)=O GYICHNKMWXRAQM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
- C07D215/60—N-oxides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epidemiology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN3600MU2012 | 2012-12-24 | ||
| IN3600/MUM/2012 | 2012-12-24 | ||
| PCT/IN2013/000796 WO2014102818A1 (en) | 2012-12-24 | 2013-12-23 | Novel quinolone derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016503052A JP2016503052A (ja) | 2016-02-01 |
| JP2016503052A5 JP2016503052A5 (https=) | 2016-06-23 |
| JP6026013B2 true JP6026013B2 (ja) | 2016-11-16 |
Family
ID=54148255
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015548889A Active JP6026013B2 (ja) | 2012-12-24 | 2013-12-23 | 新規キノロン誘導体 |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US9394300B2 (https=) |
| EP (1) | EP2935221B1 (https=) |
| JP (1) | JP6026013B2 (https=) |
| KR (1) | KR101733901B1 (https=) |
| CN (1) | CN104903295B (https=) |
| AP (1) | AP2015008502A0 (https=) |
| AR (1) | AR094300A1 (https=) |
| AU (1) | AU2013368843B2 (https=) |
| BR (1) | BR112015014222B1 (https=) |
| CA (1) | CA2894636C (https=) |
| CL (1) | CL2015001802A1 (https=) |
| EA (1) | EA028402B1 (https=) |
| ES (1) | ES2660288T3 (https=) |
| IL (1) | IL239109B (https=) |
| JO (1) | JO3781B1 (https=) |
| MA (1) | MA38138A1 (https=) |
| MX (1) | MX373392B (https=) |
| MY (1) | MY175854A (https=) |
| NZ (1) | NZ708605A (https=) |
| PH (1) | PH12015501452B1 (https=) |
| SG (1) | SG11201504458XA (https=) |
| TR (1) | TR201802305T4 (https=) |
| TW (1) | TWI598339B (https=) |
| UA (1) | UA117122C2 (https=) |
| WO (1) | WO2014102818A1 (https=) |
| ZA (1) | ZA201503814B (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016034108A1 (zh) * | 2014-09-02 | 2016-03-10 | 广东东阳光药业有限公司 | 喹啉酮类化合物及其应用 |
| WO2016045125A1 (en) * | 2014-09-28 | 2016-03-31 | Merck Sharp & Dohme Corp. | Inhibitors of hif prolyl hydroxylase |
| CL2015003047A1 (es) * | 2015-10-15 | 2016-06-17 | Univ Chile | Método ex vivo para detectar precozmente injuria renal aguda en pacientes críticos, que comprende la mediciom en una muestra de tres proteinas como biomarcadores, factor de crecimiento fibroblástico 23, klotho y eritropoyetina |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| CN108069957B (zh) * | 2016-11-09 | 2022-11-04 | 广东东阳光药业有限公司 | 脯氨酰羟化酶抑制剂及其用途 |
| CA3062972C (en) * | 2017-05-09 | 2021-09-14 | Kind Pharmaceutical | Indolizine derivatives and their application in medicine |
| JP7050165B2 (ja) | 2018-02-26 | 2022-04-07 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｂｖ複製阻害剤としての置換ピロリジン化合物 |
| WO2021181360A1 (en) * | 2020-03-13 | 2021-09-16 | Cadila Healthcare Limited | Novel salts of quinolone compounds |
| US20230190731A1 (en) * | 2020-03-17 | 2023-06-22 | Zydus Lifesciences Limited | Formulation comprising hif prolyl hydroxylase inhibitors |
| WO2021216530A1 (en) | 2020-04-20 | 2021-10-28 | Akebia Therapeutics, Inc. | Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer |
| CN115666539A (zh) * | 2020-05-29 | 2023-01-31 | 兹杜斯生命科学有限公司 | 银屑病和皮肤炎性疾病的治疗 |
| EP4157220A1 (en) * | 2020-06-01 | 2023-04-05 | Zydus Lifesciences Limited | Treatment for the inflammatory bowel disease |
| WO2022150623A1 (en) | 2021-01-08 | 2022-07-14 | Akebia Therapeutics, Inc. | Compounds and composition for the treatment of anemia |
| EP4308120A4 (en) | 2021-03-19 | 2024-11-27 | Zydus Lifesciences Limited | TREATMENT OF SICKLE CELL ANEMIA |
| WO2022195525A1 (en) * | 2021-03-19 | 2022-09-22 | Zydus Lifesciences Limited | A quinolone compound in solid forms and processes for the preparation thereof |
| WO2022238745A1 (en) * | 2021-05-14 | 2022-11-17 | Zydus Lifesciences Limited | Topical pharmaceutical composition of hif prolyl hydroxylase inhibitors |
| EP4347022A1 (en) | 2021-05-27 | 2024-04-10 | Keryx Biopharmaceuticals, Inc. | Pediatric formulations of ferric citrate |
| CN113549011B (zh) * | 2021-08-10 | 2023-05-09 | 广东东阳光药业有限公司 | 德度司他的共晶或盐及其制备方法和用途 |
| CN117836275A (zh) * | 2021-09-20 | 2024-04-05 | 载度思生命科学有限公司 | 德度司他颗粒及其组合物 |
| EP4539934A1 (en) * | 2022-06-24 | 2025-04-23 | Zydus Lifesciences Limited | Treatment for glomerular diseases |
| EP4565233A1 (en) * | 2022-08-01 | 2025-06-11 | Zydus Lifesciences Limited | Treatment for aplastic anemia (aa) |
| WO2025087207A1 (zh) | 2023-10-24 | 2025-05-01 | 杭州安道药业有限公司 | 含有缺氧诱导因子-脯酰胺羟基化酶抑制剂的长效口服药物及其应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ270267A (en) | 1993-12-30 | 1997-03-24 | Hoechst Ag | 3-hydroxypyridin-2yl (and -quinolin-2-yl) carboxamide derivatives and pharmaceutical compositions |
| WO2004108681A1 (en) | 2003-06-06 | 2004-12-16 | Fibrogen, Inc. | Nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin |
| US8703795B2 (en) * | 2005-03-02 | 2014-04-22 | Fibrogen, Inc. | Thienopyridine compounds, and methods of use thereof |
| WO2007038571A2 (en) | 2005-09-26 | 2007-04-05 | Smithkline Beecham Corporation | Prolyl hydroxylase antagonists |
| EP1960363B1 (en) * | 2005-12-09 | 2014-01-22 | Amgen, Inc. | Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions and uses thereof |
| AR059733A1 (es) * | 2006-03-07 | 2008-04-23 | Smithkline Beecham Corp | Compuesto derivado de glicina n- sustituida con heteroaromaticos bicicicos, composicion farmaceutica que lo comprende, uso para preparar un medicamento para tratar la anemia y proceso para su preparacion |
| BRPI0710527B8 (pt) * | 2006-04-04 | 2021-05-25 | Fibrogen Inc | compostos de pirrolo- e tiazolo-piridina e composição farmacêutica que os compreende |
| US20090176825A1 (en) * | 2006-05-16 | 2009-07-09 | Fitch Duke M | Prolyl hydroxylase inhibitors |
| US20100056516A1 (en) * | 2006-07-17 | 2010-03-04 | Williams Peter D | 1-hydroxy naphthyridine compounds as anti-hiv agents |
| ES2393326T3 (es) * | 2006-12-18 | 2012-12-20 | Amgen, Inc | Compuestos basados en azaquinolona que presentan actividad inhibidora de prolil hidroxilasas, composiciones y usos de los mismos |
| US8048894B2 (en) * | 2007-04-18 | 2011-11-01 | Amgen Inc. | Quinolones and azaquinolones that inhibit prolyl hydroxylase |
| JP2010524935A (ja) * | 2007-04-18 | 2010-07-22 | メルク・シャープ・エンド・ドーム・コーポレイション | 新規１，８−ナフチリジン化合物 |
| EP2155746A2 (en) * | 2007-05-04 | 2010-02-24 | Amgen, Inc | Diazaquinolones that inhibit prolyl hydroxylase activity |
| US8030346B2 (en) * | 2007-05-04 | 2011-10-04 | Amgen Inc. | Heterocyclic quinolone derivatives that inhibit prolyl hydroxylase activity |
| AU2008251031B2 (en) * | 2007-05-16 | 2013-12-19 | Norman Terry Cowper | System and method for maximising solids concentration of slurry pumped through a pipeline |
| JP2011505367A (ja) * | 2007-11-30 | 2011-02-24 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | プロリルヒドロキシラーゼ阻害剤 |
| AU2009217541A1 (en) * | 2008-02-25 | 2009-09-03 | Merck Sharp & Dohme Corp. | Tetrahydrothieno pyridines |
| CA2716798A1 (en) * | 2008-02-25 | 2009-09-03 | Merck Sharp & Dohme Corp. | Tetrahydrofuropyridones |
| CA2714111A1 (en) * | 2008-02-25 | 2009-09-03 | Merck Sharp & Dohme Corp. | Tetrahydro-1h-pyrrolo fused pyridones |
| US20110098324A1 (en) * | 2008-06-25 | 2011-04-28 | Brackley Iii James A | Prolyl hydroxylase inhibitors |
| EP3594213A1 (en) | 2009-07-17 | 2020-01-15 | Japan Tobacco Inc. | Triazolopyridine compounds and action thereof as prolyl hydroxylase inhibitors and erythropoietin production inducers |
| US20120196853A1 (en) * | 2009-08-20 | 2012-08-02 | Vifor (International) Ag | Novel Quinoline-Hepcidine Antagonists |
| WO2012106472A1 (en) | 2011-02-02 | 2012-08-09 | Fibrogen, Inc. | Naphthyridine derivatives as inhibitors of hypoxia inducible factor (hif) hydroxylase |
| EP2758058B1 (en) | 2011-09-23 | 2017-04-26 | Merck Sharp & Dohme Corp. | Substituted pyrimidines |
| CA2863279A1 (en) * | 2012-01-31 | 2013-08-08 | Toyama Chemical Co., Ltd. | Heterocyclic compound having anti-hiv activity |
-
2013
- 2013-12-23 JO JOP/2013/0383A patent/JO3781B1/ar active
- 2013-12-23 MX MX2015008233A patent/MX373392B/es active IP Right Grant
- 2013-12-23 WO PCT/IN2013/000796 patent/WO2014102818A1/en not_active Ceased
- 2013-12-23 AP AP2015008502A patent/AP2015008502A0/xx unknown
- 2013-12-23 KR KR1020157016080A patent/KR101733901B1/ko active Active
- 2013-12-23 NZ NZ708605A patent/NZ708605A/en unknown
- 2013-12-23 TR TR2018/02305T patent/TR201802305T4/tr unknown
- 2013-12-23 TW TW102147766A patent/TWI598339B/zh active
- 2013-12-23 CN CN201380067856.4A patent/CN104903295B/zh active Active
- 2013-12-23 ES ES13828997.0T patent/ES2660288T3/es active Active
- 2013-12-23 EA EA201591195A patent/EA028402B1/ru not_active IP Right Cessation
- 2013-12-23 CA CA2894636A patent/CA2894636C/en active Active
- 2013-12-23 MY MYPI2015001457A patent/MY175854A/en unknown
- 2013-12-23 BR BR112015014222-2A patent/BR112015014222B1/pt active IP Right Grant
- 2013-12-23 US US14/652,024 patent/US9394300B2/en active Active
- 2013-12-23 EP EP13828997.0A patent/EP2935221B1/en active Active
- 2013-12-23 UA UAA201506784A patent/UA117122C2/uk unknown
- 2013-12-23 SG SG11201504458XA patent/SG11201504458XA/en unknown
- 2013-12-23 AU AU2013368843A patent/AU2013368843B2/en active Active
- 2013-12-23 JP JP2015548889A patent/JP6026013B2/ja active Active
- 2013-12-27 AR ARP130105055A patent/AR094300A1/es active IP Right Grant
-
2015
- 2015-05-27 ZA ZA2015/03814A patent/ZA201503814B/en unknown
- 2015-05-29 MA MA38138A patent/MA38138A1/fr unknown
- 2015-06-01 IL IL239109A patent/IL239109B/en active IP Right Grant
- 2015-06-22 CL CL2015001802A patent/CL2015001802A1/es unknown
- 2015-06-23 PH PH12015501452A patent/PH12015501452B1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6026013B2 (ja) | 新規キノロン誘導体 | |
| JP5269086B2 (ja) | ヒト免疫不全ウイルスの複製阻害薬 | |
| KR20100108337A (ko) | 사람 면역결핍 바이러스 복제의 억제제 | |
| EP3704113A1 (en) | Bridged bicyclic compounds as farnesoid x receptor modulators | |
| JP2020527588A (ja) | アデノシンアンタゴニストとしてのヘテロ環式化合物 | |
| CA2931085A1 (en) | Cyclic sulfone and sulfoximine analogs and uses thereof | |
| EP2429993A1 (en) | Inhibitors of human immunodeficiency virus replication | |
| JP2021533186A (ja) | ブロモドメインタンパク質阻害薬としてのイミノスルホン化合物、医薬組成物及びその医薬用途 | |
| EP2220084A1 (en) | Inhibitors of human immunodeficiency virus replication | |
| TW201925173A (zh) | 鹵代烯丙基胺類ssao/vap-1抑制劑及其用途 | |
| WO2008067644A1 (en) | Inhibitors of hiv replication | |
| WO2014070978A1 (en) | Inhibitors of cytomegalovirus | |
| TWI748194B (zh) | 含有雙環核心部分之新穎lxr調節劑 | |
| JP2011513222A (ja) | テトラヒドロチエノピリジン | |
| US20200131144A1 (en) | Amine or (thio)amide containing lxr modulators | |
| HK1211022B (en) | Quinolone derivatives | |
| OA17332A (en) | Novel quinolone derivatives. | |
| KR102954013B1 (ko) | 브로모도메인 단백질 억제제로서의 설폭시민 화합물과 약학적 조성물 및 이의 의학적 용도 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A529 | Written submission of copy of amendment under article 34 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A529 Effective date: 20150821 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150821 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160506 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20160506 |
|
| A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20160517 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160523 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160803 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160912 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20161011 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6026013 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |